Expectations of Serious Adverse Events at the End-of-Life of Patients with Acute Myeloid Leukemia Who Receive Salvage Therapy

BACKGROUND: Patients with acute myeloid leukemia (AML) and refractory disease receive investigational therapies within 2 months of their death. The attribution of serious adverse events (AE) in this phase to disease progression versus drug toxicity is tenuous. We aimed to determine the incidences of...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Lymphoma Myeloma Leuk
Prif Awduron: Cardenas-Turanzas, Marylou, Ravandi-Kashani, Farhad, Cortes, Jorge E., Jabbour, Elias, Faderl, Stefan, Pierce, Sherry A., Kantarjian, Hagop
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2013
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4341913/
https://ncbi.nlm.nih.gov/pubmed/23763918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2013.03.021
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg